BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Monetary Freedom Guide: Plan Your Future - 2Women take pride in Holy Week roles after a Spanish Catholic brotherhood's procession excluded them
- 3Why Cannes Is the Ultimate New Year’s Eve Destination in the South of France’s Off-Season
- 4Fisherman Attacked by Great White Shark Says ‘My Left Foot Was in His Mouth’
- 5South Carolina's measles outbreak reaches 434 cases
- Setbacks in Texas and elsewhere put Republicans' redistricting hopes in doubt as key deadlines loom
- Instructions to Explore the Universe of Vehicle Leases
- Choosing the Ideal Bed for Quality Rest and Solace
- I'm 18 and founded an AI startup. I have to wake up at 3 a.m. to work on it before school, but it's worth every sleepless night.
- 25 of the world’s best sandwiches
- Energy agency chief warns of 'black April' for oil supplies
- The Best Traditional Music Arrangers in History
- How to sound like an astronaut as you follow the first human moon mission in more than half a century
- Exploring Being a parent: A Survey of \Bits of knowledge and Guidance for Guardians\ Nurturing Book
